Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARGOS THERAPEUTICS INCARGS · Entity 167312 | Director | January 19, 2017 | January 20, 2017 |
| HOOKIPA Pharma Inc.HOOK · Entity 15295 | Director | October 21, 2020 | October 23, 2020 |
| uniQure N.V.QURE · Entity 4162 | EVP, Research & Product Dev. | February 27, 2020 | March 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARGOS THERAPEUTICS INC
Report date January 19, 2017 · Filed January 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.85 · Expires 2027-01-18 | Direct | 9,500 |
Reported balance
After 2017-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-19 · Grant · Acquired 9,500 · Balance 9,500 |
HOOKIPA Pharma Inc.
Report date October 21, 2020 · Filed October 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,485 |
Reported balance
After 2020-10-21 transaction · row 1
1 source rowRow 1 · 2020-10-21 · Grant · Acquired 2,485 · Balance 2,485 |
uniQure N.V.
Report date February 27, 2020 · Filed March 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 61,599 |
Reported balance
After 2020-02-27 transaction · row 1
1 source rowRow 1 · 2020-02-27 · Grant · Acquired 12,380 · Balance 61,599 F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.81 · Expires 2030-02-27 | Direct | 21,719 |
Reported balance
After 2020-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-27 · Grant · Acquired 21,719 · Balance 21,719 F3: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 9,859 |
Reported balance
Holding disclosure · report date 2020-02-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,859 F2: Shares held by Forbion Management. The Reporting Person is a member of Forbion's investment committee, which exercises voting and investment power over such shares. None of the members of the investment committee have individual voting and investment power with respect to such shares, and the Reporting Person disclaims beneficial ownership of such shares except to the extent of his proportionate pecuniary interest therein. The Reporting Person is also a partner of Forbion Capital Partners, which acts as the investment advisor to the directors of ForUniQure B.V. and Forbion 1 Management B.V. (the director of ForUniQure B.V.) with respect to Ordinary Shares held by ForUniQure B.V. The Reporting Person disclaims beneficial ownership of such Ordinary Shares, except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates.
F2: Shares held by Forbion Management. The Reporting Person is a member of Forbion's investment committee, which exercises voting and investment power over such shares. None of the members of the investment committee have individual voting and investment power with respect to such shares, and the Reporting Person disclaims beneficial ownership of such shares except to the extent of his proportionate pecuniary interest therein. The Reporting Person is also a partner of Forbion Capital Partners, which acts as the investment advisor to the directors of ForUniQure B.V. and Forbion 1 Management B.V. (the director of ForUniQure B.V.) with respect to Ordinary Shares held by ForUniQure B.V. The Reporting Person disclaims beneficial ownership of such Ordinary Shares, except to the extent of his proportionate pecuniary interest therein.
F3: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 21, 2020 Filed Oct 23, 2020 16:03 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantCommon Stock | 2,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-117709 · a4.xml · nonDerivative · entry 1 van Deventer Sander · CIK 0001543084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,485 Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 16:28 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0001104659-20-075260 · a4.xml · derivative · entry 1 van Deventer Sander · CIK 0001543084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2030-06-18 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on June 18, 2021. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 15:38 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 21,719 | $0.00 Strike: $51.81 | $0.00 |
DisclosureSEC source: 0000904454-20-000251 · edgar.xml · derivative · entry 3 van Deventer Sander · CIK 0001543084 · EVP, Research & Product Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,719 Underlying: Ordinary Shares · 21,719 shares Expires 2030-02-27 F3 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 15:38 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 12,380 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000251 · edgar.xml · nonDerivative · entry 1 van Deventer Sander · CIK 0001543084 · EVP, Research & Product Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,599 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| January 31, 2020 Filed Jan 31, 2020 16:13 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 6,092 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000132 · edgar.xml · nonDerivative · entry 1 van Deventer Sander · CIK 0001543084 · EVP, Research & Product Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,219 F1 · shares: Represents performance-based restricted share units ("PRSUs") granted on January 25, 2019 to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated, which vested on January 31, 2020. Each PRSU represents the contingent right to receive one Ordinary Share. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 21:11 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 923 | $62.10 | $57,318.30 |
DisclosureSEC source: 0000904454-20-000114 · edgar.xml · nonDerivative · entry 2 van Deventer Sander · CIK 0001543084 · EVP, Research & Product Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,127 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.85 to $61.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 21:11 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,304 | $61.27 | $79,896.08 |
DisclosureSEC source: 0000904454-20-000114 · edgar.xml · nonDerivative · entry 1 van Deventer Sander · CIK 0001543084 · EVP, Research & Product Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,050 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.85 to $61.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2019 Filed Jan 3, 2020 16:03 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001104659-20-000850 · a4.xml · derivative · entry 1 van Deventer Sander · CIK 0001543084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2029-12-18 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on December 18, 2020. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 09:39 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000642 · edgar.xml · nonDerivative · entry 1 van Deventer Sander · CIK 0001543084 · EVP, Research & Product Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,354 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. F2 · balance_after: Adjusted to reflect the inadvertent overstatement of the Reporting Person's holdings by 100 shares in his last Form 4 filed on 01/30/2019. Read SEC document |
| April 17, 2019 Filed Apr 24, 2019 17:32 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 19,200 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-19-023443 · a4.xml · derivative · entry 1 van Deventer Sander · CIK 0001543084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Underlying: Common Stock · 19,200 shares Expires 2029-04-17 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on April 17, 2020, with the remainder vesting in 8 equal quarterly installments thereafter. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 17:01 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,358 | $31.31 | $42,518.98 |
DisclosureSEC source: 0000904454-19-000126 · edgar.xml · nonDerivative · entry 1 van Deventer Sander · CIK 0001543084 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,313 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $31.39. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Shares held by SJH van Deventer C.V., an entity affiliated with Forbion Capital Partners ("FCP"), or required to be transferred to FCP under the Reporting Person's employment agreement with FCP. The Reporting Person has a partial beneficial interest in such shares as a managing partner of FCP, however he disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 20:47 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 18,325 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0000904454-19-000115 · edgar.xml · derivative · entry 3 van Deventer Sander · CIK 0001543084 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,325 Underlying: Ordinary Shares · 18,325 shares Expires 2029-01-25 F4 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 20:47 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 10,913 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000115 · edgar.xml · nonDerivative · entry 2 van Deventer Sander · CIK 0001543084 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 41,571 F3 · shares: Represents performance-based restricted share units ("PRSUs") granted on January 26, 2018 to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated, which vested on January 25, 2019. Each PRSU represents the contingent right to receive one Ordinary Share. F2 · ownership.nature: Shares held by SJH van Deventer C.V., an entity affiliated with Forbion Capital Partners ("FCP"), or required to be transferred to FCP under the Reporting Person's employment agreement with FCP. The Reporting Person has a partial beneficial interest in such shares as a managing partner of FCP, however he disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 20:47 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 5,589 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000115 · edgar.xml · nonDerivative · entry 1 van Deventer Sander · CIK 0001543084 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 30,658 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. F2 · ownership.nature: Shares held by SJH van Deventer C.V., an entity affiliated with Forbion Capital Partners ("FCP"), or required to be transferred to FCP under the Reporting Person's employment agreement with FCP. The Reporting Person has a partial beneficial interest in such shares as a managing partner of FCP, however he disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 10:42 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 5,985 | $18.53 | $110,902.05 |
DisclosureSEC source: 0000904454-18-000093 · edgar.xml · nonDerivative · entry 1 van Deventer Sander · CIK 0001543084 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,069 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.41 to $18.69. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Shares held by SJH van Deventer C.V., an entity affiliated with Forbion Capital Partners ("FCP"), or required to be transferred to FCP under the Reporting Person's employment agreement with FCP. The Reporting Person has a partial beneficial interest in such shares as a managing partner of FCP, however he disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 13:11 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 20,788 | $0.00 Strike: $19.39 | $0.00 |
DisclosureSEC source: 0000904454-18-000084 · edgar.xml · derivative · entry 2 van Deventer Sander · CIK 0001543084 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,788 Underlying: Ordinary Shares · 20,788 shares Expires 2028-01-26 F4 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 13:11 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 7,795 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000084 · edgar.xml · nonDerivative · entry 1 van Deventer Sander · CIK 0001543084 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (2) Disclosed balance after: 31,054 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. F2 · balance_after: Includes (i) 9,859 Ordinary Shares held by SJH van Deventer C.V., an entity affiliated with Forbion Capital Partners ("FCP"). The Reporting Person has a partial beneficial interest in such shares as a managing partner of FCP, however he disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. (ii) 5,000 restricted share units that vested in full on January 27, 2017 previously disclosed by the Reporting Person in Table II; and (iii) 11,000 restricted share units that vested in full on January 27, 2018 previously disclosed by the Reporting Person in Table II. Under the Reporting Person's employment agreement with FCP, he is required to transfer the restricted share units to FCP. The Reporting Person has a partial beneficial interest in such restricted share units as a managing partner of FCP, however he disclaims beneficial ownership of such restricted share units except to the extent of his pecuniary interest therein. F3 · balance_after: Adjusted to reflect the sale on January 30, 2017 of 2,600 shares to satisfy tax withholding obligations in connection with the vesting of restricted share units, the proceeds of which were remitted to the Issuer, as required by the relevant Restricted Share Unit Agreement. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 16:34 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $8.49 | $0.00 |
DisclosureSEC source: 0001209191-17-053713 · doc4.xml · derivative · entry 1 van Deventer Sander · CIK 0001543084 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 150,000 shares Expires 2027-09-20 F1 · derivative.exercise_date: The first tranche of 25% vests on September 20, 2018, with the remainder vesting in tranches of 6.25% each quarter thereafter over three years. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:17 UTC | uniQure N.V. QURE · Entity 4162 | GrantRestricted Stock Units · Derivative | 11,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003707 · doc1.xml · derivative · entry 2 van Deventer Sander · CIK 0001543084 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Managing Partner Disclosed balance after: 16,000 Underlying: Ordinary Shares · 11,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Unit vests 100% on January 27, 2018. F3 · derivative.expiration_date: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. F4 · ownership.nature: Under Mr. van Deventer's employment agreement with Forbion Capital Partners, he is required to transfer the Restricted Stock Units and stock options to Forbion Capital Partners. As a managing partner of Forbion Capital Partners, Mr. van Deventer has a partial beneficial interest in the Restricted Stock Units and stock options transferred to Forbion Capital Partners. Mr. van Deventer disclaims beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:17 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003707 · doc1.xml · derivative · entry 1 van Deventer Sander · CIK 0001543084 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Managing Partner Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 100% on January 27, 2018. F4 · ownership.nature: Under Mr. van Deventer's employment agreement with Forbion Capital Partners, he is required to transfer the Restricted Stock Units and stock options to Forbion Capital Partners. As a managing partner of Forbion Capital Partners, Mr. van Deventer has a partial beneficial interest in the Restricted Stock Units and stock options transferred to Forbion Capital Partners. Mr. van Deventer disclaims beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 13:46 UTC | ARGOS THERAPEUTICS INC ARGS · Entity 167312 | GrantStock Option (right to buy) · Derivative | 9,500 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001543084-17-000001 · primary_doc.xml · derivative · entry 1 van Deventer Sander · CIK 0001543084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2027-01-18 Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 11:28 UTC | ARGOS THERAPEUTICS INC ARGS · Entity 167312 | GrantCommon Stock | 2,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001543084-16-000005 · primary_doc.xml · nonDerivative · entry 1 van Deventer Sander · CIK 0001543084 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,057 F1 · shares: The reporting person has received a fully vested stock award for shares of the Company's common stock. For calendar year 2016, the Company has elected to make common stock awards in lieu of cash payments of director fees otherwise payable under the director compensation policy. The number of shares of common stock awarded represent the quotient of (A) such director fees divided by (B) the Company's closing stock price on the date awarded, rounded down to the nearest whole share of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.